Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 4/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | OXTR | P30559 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2365865 | 1.00 | PIK3CA (0.35) | PIK3CAPIK3C3SLC6A9SLC6A5IDH1 | |
| SCHEMBL2366433 | 0.93 | TP53 (0.32) | PIK3C3SLC6A9SLC6A5IDH1TP53 | |
| SCHEMBL2366426 | 0.93 | TP53 (0.32) | PIK3C3SLC6A9SLC6A5IDH1TP53 | |
| SCHEMBL2366020 | 0.93 | P2RX3 (0.33) | PIK3C3SLC6A9SLC6A5IDH1TP53 | |
| SCHEMBL2366012 | 0.93 | P2RX3 (0.33) | PIK3C3SLC6A9SLC6A5IDH1TP53 | |
| SCHEMBL2365885 | 0.92 | PIK3CA (0.35) | PIK3CAPIK3C3SLC6A9SLC6A5IDH1 | |
| SCHEMBL2365877 | 0.92 | PIK3CA (0.35) | PIK3CAPIK3C3SLC6A9SLC6A5IDH1 | |
| SCHEMBL2366290 | 0.91 | P2RY12 (0.33) | TP53LMNAMAPTTHRB | |
| SCHEMBL2366294 | 0.91 | P2RY12 (0.33) | TP53LMNAMAPTTHRB | |
| SCHEMBL2366804 | 0.90 | PIK3CA (0.34) | PIK3CAPIK3C3SLC6A9SLC6A5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364975-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2364975-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263571-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | PIK3CA 4648/4885PIK3C3 1410/4885SLC6A9 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.